No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
20 mg bid of pf-02545920 |
- |
- |
- |
- |
1件: 8 |
2 |
20mg daily citalopram |
Citalopram |
D00822, D07704 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
1件: 8 |
3 |
[123i]mni-420 |
- |
- |
- |
- |
2件: 6, 8 |
4 |
[18f]fpeb |
- |
- |
- |
- |
3件: 6, 8, 206 |
5 |
Acr16 |
Acr16 |
- |
- |
- |
1件: 8 |
6 |
Acr16 10 mg |
Acr16 |
- |
- |
- |
1件: 8 |
7 |
Acr16 22.5 mg |
Acr16 |
- |
- |
- |
1件: 8 |
8 |
Acr16 45 mg |
Acr16 |
- |
- |
- |
1件: 8 |
9 |
Acr16 hydrochloride, asp2314 hydrochloride, fr310826 |
Acr16 |
- |
- |
- |
1件: 8 |
10 |
Afq056 |
- |
- |
- |
- |
3件: 6, 8, 206 |
11 |
Alprazolam |
Alprazolam |
D00225 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
1件: 8 |
12 |
Amantadine |
Amantadine |
D00777, D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
4件: 6, 8, 13, 127 |
13 |
Atomoxetine |
Atomoxetine |
D02574, D07473 |
1件: SLC6A2 |
1件: Synaptic vesicle cycle |
3件: 6, 8, 13 |
14 |
Autologous stem cell |
- |
- |
- |
- |
1件: 8 |
15 |
Bevantolol |
Bevantolol |
- |
- |
- |
1件: 8 |
16 |
Bevantolol hydrochloride |
Bevantolol |
- |
- |
- |
1件: 8 |
17 |
Blood sample |
- |
- |
- |
- |
12件: 8, 13, 46, 49, 51, 53, 61, 66, 97, 274, 288, 299 |
18 |
Bn82451b |
- |
- |
- |
- |
1件: 8 |
19 |
Bn8251b |
- |
- |
- |
- |
1件: 8 |
20 |
Bupropion |
Bupropion |
D00817, D07591, D07938 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
2件: 8, 96 |
21 |
Calvan® 100 mg |
- |
- |
- |
- |
1件: 8 |
22 |
Cellavita hd higher dose |
- |
- |
- |
- |
1件: 8 |
23 |
Cellavita hd lower dose |
- |
- |
- |
- |
1件: 8 |
24 |
Citalopram |
Citalopram |
D00822, D07704 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 8, 46, 127 |
25 |
Coenzyme q10 |
Ubidecarenone |
D01065 |
- |
- |
10件: 2, 6, 8, 10, 46, 57, 113, 193, 214, 215 |
26 |
Coq10 |
Ubidecarenone |
D01065 |
- |
- |
3件: 5, 6, 8 |
27 |
Creatine |
Creatine |
- |
- |
- |
12件: 1, 2, 5, 6, 8, 13, 46, 49, 50, 113, 156, 201 |
28 |
Creatine monohydrate |
Creatine |
- |
- |
- |
4件: 2, 8, 113, 156 |
29 |
Cystagon |
Cysteamine |
D03634, D03635 |
- |
- |
3件: 8, 19, 299 |
30 |
Cysteamine |
Cysteamine |
D03634, D03635 |
- |
- |
4件: 8, 19, 21, 299 |
31 |
Cysteamine bitartrate |
Cysteamine |
D03634, D03635 |
- |
- |
4件: 8, 19, 21, 299 |
32 |
Dextromethorphan |
Dextromethorphan |
D00848, D03742, D03744 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
9件: 2, 6, 8, 13, 46, 78, 96, 97, 156 |
33 |
Dextromethorphan/quinidine 20mg/10mg (dm/q 20mg/10mg) |
Dextromethorphan |
D00848, D03742, D03744 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 8 |
34 |
Digoxin |
Digoxin |
D00298 |
4件: ATP1A1, ATP1A2, ATP1A3, ATP1A4 |
18件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Bile secretion, Carbohydrate digestion and absorption, Cardiac muscle contraction, Endocrine and other factor-regulated calcium reabsorption, Gastric acid secretion, Insulin secretion, Mineral absorption, Pancreatic secretion, Protein digestion and absorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Thyroid hormone signaling pathway, Thyroid hormone synthesis, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 8, 46 |
35 |
Dimebon |
Latrepirdine |
D09917 |
6件: ACHE, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
19件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Glycerophospholipid metabolism, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 8 |
36 |
Dimebon (latrepirdine) |
Latrepirdine |
D09917 |
6件: ACHE, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
19件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Glycerophospholipid metabolism, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 8 |
37 |
Dimebon + dextromethorphan |
Dextromethorphan |
D00848, D03742, D03744 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 8 |
38 |
Dimebon + ketoconazole |
Ketoconazole |
D00351 |
1件: CYP17A1 |
6件: Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Steroid hormone biosynthesis |
1件: 8 |
39 |
Dimebon + omeprazole |
Omeprazole |
D00455, D01207, D05259, D05261 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
1件: 8 |
40 |
Dimebon alone |
Latrepirdine |
D09917 |
6件: ACHE, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
19件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Glycerophospholipid metabolism, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 8 |
41 |
Dimebon dihydrochloride |
Latrepirdine |
D09917 |
6件: ACHE, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
19件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Glycerophospholipid metabolism, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 8 |
42 |
Dimebon ir |
Latrepirdine |
D09917 |
6件: ACHE, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
19件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Glycerophospholipid metabolism, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 8 |
43 |
Dimebon ir tablet |
Latrepirdine |
D09917 |
6件: ACHE, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
19件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Glycerophospholipid metabolism, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 8 |
44 |
Dimebon mr1 |
Latrepirdine |
D09917 |
6件: ACHE, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
19件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Glycerophospholipid metabolism, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 8 |
45 |
Dimebon mr2 |
Latrepirdine |
D09917 |
6件: ACHE, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
19件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Glycerophospholipid metabolism, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 8 |
46 |
Dimebon mr3 |
Latrepirdine |
D09917 |
6件: ACHE, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
19件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Glycerophospholipid metabolism, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 8 |
47 |
Dimebon mr4 |
Latrepirdine |
D09917 |
6件: ACHE, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
19件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Glycerophospholipid metabolism, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 8 |
48 |
Dimebon transdermal |
Latrepirdine |
D09917 |
6件: ACHE, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
19件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Glycerophospholipid metabolism, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 8 |
49 |
Divalproex |
Valproic acid |
D00399 |
7件: ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 |
17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
1件: 8 |
50 |
Ethyl-epa |
Icosapent ethyl |
D01892 |
- |
- |
1件: 8 |
51 |
Ethyl-epa (miraxion™) |
Icosapent ethyl |
D01892 |
- |
- |
1件: 8 |
52 |
Fenofibrate |
Fenofibrate |
D00565 |
1件: PPARA |
7件: Adipocytokine signaling pathway, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease (NAFLD), PPAR signaling pathway, cAMP signaling pathway |
5件: 8, 79, 93, 94, 265 |
53 |
Graft intracerebral of foetal neurons |
- |
- |
- |
- |
1件: 8 |
54 |
Gsk356278 |
Gsk356278 |
- |
- |
- |
1件: 8 |
55 |
Haloperidol |
Haloperidol |
D00136, D01898 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 8 |
56 |
Hyperium |
Rilmenidine |
D08482 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 8 |
57 |
Isis 443139 10 mg |
- |
- |
- |
- |
1件: 8 |
58 |
Isis 443139 120 mg |
- |
- |
- |
- |
1件: 8 |
59 |
Isis 443139 30 mg |
- |
- |
- |
- |
1件: 8 |
60 |
Isis 443139 60 mg |
- |
- |
- |
- |
1件: 8 |
61 |
Isis 443139 90 mg |
- |
- |
- |
- |
1件: 8 |
62 |
Ketoconazole |
Ketoconazole |
D00351 |
1件: CYP17A1 |
6件: Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Steroid hormone biosynthesis |
3件: 8, 13, 75 |
63 |
Laquinimod |
Laquinimod |
- |
- |
- |
4件: 8, 13, 49, 96 |
64 |
Latrepirdine |
Latrepirdine |
D09917 |
6件: ACHE, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
19件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Glycerophospholipid metabolism, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
1件: 8 |
65 |
Lax-101 |
- |
- |
- |
- |
1件: 8 |
66 |
Lithium |
Lithium citrate |
D04749 |
- |
- |
4件: 2, 5, 7, 8 |
67 |
Memantine |
Memantine |
D04905, D08174 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
7件: 2, 6, 8, 13, 49, 127, 205 |
68 |
Minocycline |
Minocycline |
D00850, D05045 |
- |
- |
13件: 2, 6, 8, 13, 46, 85, 90, 94, 162, 201, 206, 280, 299 |
69 |
N.a. |
- |
- |
- |
- |
8件: 3, 6, 8, 13, 46, 97, 240, 256 |
70 |
Neflamapimod |
Neflamapimod |
D10959 |
4件: MAPK11, MAPK12, MAPK13, MAPK14 |
53件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Amyotrophic lateral sclerosis (ALS), C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Dopaminergic synapse, Endocrine resistance, Epithelial cell signaling in Helicobacter pylori infection, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hepatitis B, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, IL-17 signaling pathway, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Leukocyte transendothelial migration, MAPK signaling pathway, NOD-like receptor signaling pathway, Neurotrophin signaling pathway, Oocyte meiosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathogenic Escherichia coli infection, Pertussis, Platelet activation, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rap1 signaling pathway, Relaxin signaling pathway, Retrograde endocannabinoid signaling, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Thermogenesis, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, VEGF signaling pathway, Yersinia infection |
1件: 8 |
71 |
Nilotinib |
Nilotinib |
D08953 |
4件: ABL1, KIT, PDGFRA, PDGFRB |
33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
5件: 6, 8, 34, 51, 86 |
72 |
Nilotinib 150 mg |
Nilotinib |
D08953 |
4件: ABL1, KIT, PDGFRA, PDGFRB |
33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
1件: 8 |
73 |
Olanzapine |
Olanzapine |
D00454, D06623 |
11件: ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR2A, HTR2B, HTR2C, HTR6 |
16件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Salivary secretion, Serotonergic synapse, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 2, 8 |
74 |
Omeprazole |
Omeprazole |
D00455, D01207, D05259, D05261 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
15件: 6, 8, 13, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
75 |
Osu6162 similar to (-)-osu 6162 |
- |
- |
- |
- |
2件: 6, 8 |
76 |
Pbf-999 |
- |
- |
- |
- |
1件: 8 |
77 |
Pbf-999 / 160 mg |
- |
- |
- |
- |
1件: 8 |
78 |
Pbf-999 / 320 mg |
- |
- |
- |
- |
1件: 8 |
79 |
Pbt2 |
- |
- |
- |
- |
1件: 8 |
80 |
Pf-02545920 |
- |
- |
- |
- |
1件: 8 |
81 |
Phenylbutyrate |
Phenylbutyric acid |
D05868 |
- |
- |
10件: 2, 3, 6, 8, 93, 94, 244, 251, 297, 299 |
82 |
Phosphorus |
Phosphorus |
- |
- |
- |
1件: 8 |
83 |
Pridopidine |
Pridopidine |
D09953 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
2件: 6, 8 |
84 |
Pridopidine (90 mg) |
Pridopidine |
D09953 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
1件: 8 |
85 |
Quinidine |
Quinidine |
D00642, D00643, D02272, D08458 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
3件: 2, 8, 13 |
86 |
Ramelteon |
Ramelteon |
D02689 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
3件: 6, 8, 46 |
87 |
Resveratrol |
Resveratrol |
- |
- |
- |
3件: 8, 89, 113 |
88 |
Rg6042, formerly isis 443139, ionis-httrx |
- |
- |
- |
- |
1件: 8 |
89 |
Rilmenidine |
Rilmenidine |
D08482 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 8 |
90 |
Riluzole |
Riluzole |
D00775 |
14件: GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway |
7件: 2, 3, 5, 8, 13, 17, 206 |
91 |
Risperidone |
Risperidone |
D00426 |
2件: DRD2, HTR2A |
11件: Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, cAMP signaling pathway |
5件: 8, 156, 179, 187, 206 |
92 |
Ro 723-4292/f02 |
- |
- |
- |
- |
1件: 8 |
93 |
Ro7234292 |
- |
- |
- |
- |
1件: 8 |
94 |
Ro7234292 (rg6042) |
- |
- |
- |
- |
1件: 8 |
95 |
Rolipram |
Rolipram |
D01783 |
4件: PDE4A, PDE4B, PDE4C, PDE4D |
5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway |
2件: 8, 13 |
96 |
Rp 103 |
- |
- |
- |
- |
2件: 8, 19 |
97 |
Rp103 |
- |
- |
- |
- |
2件: 8, 19 |
98 |
Sage |
Sage |
- |
- |
- |
2件: 6, 8 |
99 |
Sage-718 |
Sage |
- |
- |
- |
1件: 8 |
100 |
Sbt-020 |
- |
- |
- |
- |
1件: 8 |
101 |
Sd-809 |
- |
- |
- |
- |
1件: 8 |
102 |
Selisistat |
Selisistat |
- |
- |
- |
1件: 8 |
103 |
Sen0014196 |
- |
- |
- |
- |
1件: 8 |
104 |
Sodium phenylbutyrate |
Phenylbutyric acid |
D05868 |
- |
- |
4件: 2, 3, 8, 251 |
105 |
Som3355 100mg bid |
- |
- |
- |
- |
1件: 8 |
106 |
Som3355 200mg bid |
- |
- |
- |
- |
1件: 8 |
107 |
Srx246 |
- |
- |
- |
- |
1件: 8 |
108 |
Ss-20 |
- |
- |
- |
- |
1件: 8 |
109 |
Tetrabenazine |
Tetrabenazine |
D08575 |
1件: SLC18A2 |
7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Serotonergic synapse, Synaptic vesicle cycle |
1件: 8 |
110 |
Tetrabenazine withdrawal |
Tetrabenazine |
D08575 |
1件: SLC18A2 |
7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Serotonergic synapse, Synaptic vesicle cycle |
1件: 8 |
111 |
Tiapridal |
- |
- |
- |
- |
1件: 8 |
112 |
Triheptanoin |
Triheptanoin |
D11465 |
- |
- |
10件: 2, 8, 120, 149, 156, 248, 256, 257, 317, 324 |
113 |
Triheptanoin 1g/kg/day |
Triheptanoin |
D11465 |
- |
- |
1件: 8 |
114 |
Triheptanoin oil |
Triheptanoin |
D11465 |
- |
- |
1件: 8 |
115 |
Tv-7820 |
- |
- |
- |
- |
1件: 8 |
116 |
Ubiquinol |
Ubiquinol |
- |
- |
- |
3件: 6, 8, 17 |
117 |
Ursodiol |
Ursodeoxycholic acid |
D00734 |
1件: NR1H4 |
1件: Bile secretion |
6件: 8, 20, 93, 97, 234, 299 |
118 |
Ux007 |
- |
- |
- |
- |
4件: 8, 248, 256, 257 |
119 |
Valbenazine |
Valbenazine |
D10675 |
1件: SLC18A2 |
7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Serotonergic synapse, Synaptic vesicle cycle |
1件: 8 |
120 |
Vx15/2503 |
Pepinemab |
D11469 |
1件: SEMA4D |
1件: Axon guidance |
2件: 8, 13 |
121 |
Warfarin |
Warfarin |
D00564, D01280, D08682 |
2件: NQO1, VKORC1 |
5件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
10件: 6, 8, 13, 19, 46, 49, 66, 85, 88, 96 |
122 |
Wve-120101 |
- |
- |
- |
- |
1件: 8 |
123 |
Wve-120102 |
- |
- |
- |
- |
1件: 8 |
124 |
Xenazine |
Tetrabenazine |
D08575 |
1件: SLC18A2 |
7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Serotonergic synapse, Synaptic vesicle cycle |
1件: 8 |
125 |
Zoloft |
Sertraline |
D00825, D02360 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
1件: 8 |